23 results about "Autoimmune responses" patented technology

The present disclosure describes methods of specifically modulating the activity and / or number of regulatory T (Treg) cells within a tumor in a subject. Such methods may be used to reduce the number of regulatory T cells within a tumor in a subject, as well as to inhibit tumor growth in a subject with cancer without eliciting an autoimmune response. This method relies on the inhibition of CD36 or PPARbeta.

The invention belongs to the field of biological medicine, and discloses a membrane binding type IL7 fusion protein, an engineered immune cell for expressing the membrane binding type IL7 fusion protein and application of the membrane binding type IL7 fusion protein. The fusion protein comprises an IL7 region and a transmembrane domain and can be expressed on a cell membrane, the tumor cell killing ability and the T cell survival ability of T cells expressing the fusion protein are both enhanced, and the aims of improving the tumor immune cell treatment effect and reducing the toxic and side effects are achieved. Particularly, the IL7 fusion protein anchors and expresses IL7 on the surface of a cell through transmembrane domains such as CD80 or PD-L1 and the like, so that (1) immune cells can be accurately regulated and controlled, the possibility that an excessive IL7 signal possibly causes autoimmune response or aggravates CRS is reduced, and the safety of the IL7 to immune cells such as T cells and the like is enhanced; (2) the half-life period of IL7 is prolonged, and the anti-tumor effect of adoptive immune cells is enhanced; and (3) the transmembrane fragment is linked with the IL7 through a hinge region of the flexible linker G4S, CD80 or PD-L1, so that the flexibility of the IL7 is enhanced, and the proliferation and killing functions of the IL7 on T cells are enhanced.

This invention relates to the field of traditional Chinese medicine and natural medicines, and discloses a traditional Chinese medicine composition for treating thyroiditis, nodular goiter, and thyroid nodules, as well as its preparation method and application. The traditional Chinese medicine composition is made from raw materials in parts by weight of 1-30 parts of Prunella vulgaris, 1-30 parts of Taraxacum mongolicum, 1-30 parts of Hordeum vulgare malt, 1-20 parts of Citrus reticulata peel, 1-24 parts of Crataegus pinnatifida, and 1-24 parts of Raphanus sativus seed. It can not only significantly reduce serum TgAb and TPOAb antibody levels, inhibiting the attack of autoimmune response on the thyroid gland from the source, but also effectively reduce lymphocyte infiltration, repair damaged thyroid follicular structure and restore colloid content, thereby reversing immune damage and tissue destruction of the thyroid gland, reducing thyroid nodules, and solving the problems of existing treatments for thyroiditis, nodular goiter, and thyroid nodules that cannot reverse immune damage to the thyroid gland, destruction of follicular structure, and tissue fibrosis.

The present disclosure provides inter alia, molecules comprising an autoantibody-binding domain and at least one modified Fc domain. The present disclosure also provides methods and compositions that allow for selective depletion and / or neutralization of pathogenic autoantibodies.

The invention provides a fusion protein, a nucleic acid construct encoding the fusion protein and regulatory T-cells (Treg) expressing the fusion protein for use in the treatment of inflammatory bowel disease, wherein the fusion protein is a chimeric antigen receptor (CAR) having a single chain variable fragment (scFv) domain specific for being activated by the location of inflammatory bowel disease, especially binding to one of meprin 1α (MEP1A) and cadherin 17 (CDH17), a transmembrane domain and at least one intracellular signalling domain. The scFv domains specific for MEP1A or CDH17 have been found to selectively bind to intestine afflicted by inflammatory bowel disease and to activate suppressive activity in Treg expressing the CAR at the location of inflammatory bowel disease. Specifically, the invention provides a CAR for use in the treatment of an immune response, e.g. in the treatment of an autoimmune response, which is directed against MEP1A or directed against CDH17.

The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

Human herpesviruses can infect barrier and immune cells of the intestinal tract to cause microbiome dysbiosis and inflammation. Microbiome dysbiosis can affect the availability of nutrients required for normal brain function. Inflammation can compromise the intestinal barrier and lead to microbial translocation. Microbial translocation can cause brain infection or a mimicry auto-immune response. The embodiments restrict herpesvirus activity and injury by 1) the oral administration of exosomes containing factors to inhibit viral activity and restore homeostasis, and 2) the oral administration of recombinant bacteria that produce exosomes containing factors to inhibit viral activity and restore homeostasis. Another embodiment is the treatment of alpha-HHVs mediated intestinal dysfunction by nucleoside analogs, such as famciclovir, which may be combined with anti-viral exosome therapy.

To provide a consensus prostate antigen, a nucleic acid molecule encoding the same, a vaccine containing the same and use thereof.SOLUTION: Provided herein are consensus amino acid sequences of prostate antigens capable of breaking tolerance in a target species, including PSA, PSMA, STEAP, and PSCA antigens. Also provided are nucleic acid sequences encoding a consensus amino acid sequence of one or more of the prostate antigens PSA, PSMA, STEAP, and PSCA, as well as genetic constructs / vectors and vaccines expressing such sequences. Also provided herein are methods of generating an autoimmune response against prostate cancer cells by administering one or more of the provided vaccines, proteins, and / or nucleic acid sequences.SELECTED DRAWING: None

The present invention relates to tetrahydrobenzo-isoquinoline sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

The invention discloses a humanized monoclonal antibody of a beta1-adrenergic receptor as well as a kit and application of the humanized monoclonal antibody. The amino acid sequence of the humanized monoclonal antibody of the beta1-adrenergic receptor is as shown in SEQ ID No.1. The invention further discloses a preparation method of the humanized monoclonal antibody of the beta1-adrenergic receptor. According to the distribution condition of myocardial antigenic determinants, polypeptides of natural antigenic determinants are designed and synthesized to immunize animals to prepare monoclonal antibodies and carry out humanized expression, so that the antibody detection kit is prepared. The kit can be used for auxiliary diagnosis of autoimmune response activation and prognosis judgment of patients with viral myocarditis and dilated cardiomyopathy, and auxiliary establishment of a patient treatment scheme.

The present invention relates to a composition for preventing or treating Behcet's disease and rheumatoid arthritis, the composition containing a peptide or a mixture thereof as an active ingredient. More specifically, an intraperitoneal injection or application of P1 to P5 peptides or a mixture thereof as a skin external preparation to a mouse animal model having Behcet's disease caused by autoimmune response was found to ameliorate skin ulcers and skin inflammation in the Behcet's disease mouse model, and an arthritis amelioration effect on a rheumatoid arthritis animal model was also observed. Accordingly, the composition containing P1 to P5 peptides or mixtures thereof as active ingredients can be provided as medicine for Behcet's disease and rheumatoid arthritis.

The present invention relates to a peptide for treating inflammation and wounds and, more specifically, to use of a peptide for treating inflammation and wounds, wherein the peptide binds to collagen type VII exposed by damage to tissue and recognizes collagen type VII as an antigen, thereby inhibiting the induction of an immune response, and thus having a function of inhibiting inflammation caused by an autoimmune response, and has the function of promoting wound healing by promoting cell proliferation and migration to a wound site in the damaged tissue. The peptide according to the present invention has the binding ability to collagen type VII, and thus inhibits an immune response caused by collagen type VII, thereby inhibiting inflammation caused by an autoimmune response. In addition, the peptide can bind to the integrin beta 1 of intestinal epithelial cells and increase the cell adhesion and migration via phosphor-FAK signal and tight junction markers are increased via FAK-RhoA signal and thus promote intestine regeneration.

This invention provides combinations of kynurenine and antigen presenting cells (APC) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of Type 1 Diabetes (TID)) or alopecia areata (AA). Uses of kynurenine and antigen presenting cells (APC) as an immune modulator for the treatment of TID or AA are also provided.

This disclosure relates to modulating IL-2 expression / activity to prevent or treat diseases (cancer, autoimmune diseases, inflammatory diseases, or infections). Compounds of formula (I), as well as compositions comprising their conjugates, complexes, and pharmaceutical compositions, as well as methods of using them to modulate (e.g., increase) IL-2 expression / activity to achieve desired results (e.g., reduction in cancer cell viability, growth, proliferation, or metastasis; reduction in tumor volume; increase in survival; increase or decrease in immune cell proliferation or activation; increase or decrease in cytokine production; decrease in autoimmunity; decrease in inflammation, etc.). Related pharmaceuticals, kits, and methods of delivering such compositions are described. Compounds of formula (I) and methods for developing or manufacturing their pharmaceutical compositions are provided. Diagnostic and test methods for detecting levels of IL-2 expression / activity, as well as compositions constituting diagnostic or test kits, are further described. JPEG2026513223000025.jpg3642

The invention discloses a pMHC binding agent and application thereof. The antigen peptide-major histocompatibility complex binding agent comprises four RNA molecules, wherein the first RNA molecule comprises an antigen peptide, a DRB1 * 13: 02 beta chain, a mouse I-Eb binding segment and nucleic acid molecules coded by CD28 and CD3 zeta proteins of transmembrane and intracellular segments; the second RNA molecule comprises CMV, CD74, an antigen peptide and a nucleic acid molecule coded by a red visible spectrum fluorescent protein; the third RNA molecule comprises CD4 and a nucleic acid molecule coded by a T cell surface receptor binding region peptide sequence; and the fourth RNA molecule comprises mCD40L and a nucleic acid molecule coded by a binding peptide fragment for recognizing pMHC. According to the present invention, the antigen peptide-major histocompatibility complex II type molecule and the T cell surface receptor can be efficiently and specifically combined so as to promote the activation of the target cell surface receptor so as to achieve the efficient autoimmune reaction;

The application discloses application of CADM3 in preparation of products for treating autoimmune diseases, belongs to the technical field of biological medicine, and the amino acid sequence of the CADM3 is shown as SEQ ID NO.2.The application discloses that CADM3 is up-regulated on the surface of activated APC, in vitro cell intervention experiments are carried out by using prepared hCADM3-Ig fusion protein, it is confirmed that the fusion protein can effectively block the activation and proliferation of T cells, and further regulate the overactive autoimmune response.Through animal experiment verification, compared with the control group, the hCADM3-Ig fusion protein treatment group can significantly improve the neurological deficit symptoms of EAE model mice, obviously reduce the intestinal dysfunction of IBD model mice, effectively reduce the degree of inflammatory reaction in the two models, and significantly inhibit the activation and proliferation of pathological T cells.

The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular, disorders caused by the interaction of IgE with the FcεRI receptor.

The invention is applicable to the technical field of traditional Chinese medicine powder for treating arthralgia and provides traditional Chinese medicine powder for treating arthralgia and a preparation method thereof, and the traditional Chinese medicine powder for treating arthralgia comprises the following substances in parts by mass: 8-12 parts of tripterygium wilfordii, 4-6 parts of ligusticum wallichii, 8-12 parts of salvia miltiorrhiza, 1.6-2.4 parts of mirabilite and 4-6 parts of rheum officinale. According to the traditional Chinese medicine steeping powder for treating arthralgia and the preparation method of the traditional Chinese medicine steeping powder, the traditional Chinese medicine steeping powder takes four mechanisms of immunoregulation, anti-inflammation, blood circulation activation and detumescence as a core, accurate strike on the pathological link of rheumatoid arthritis is formed, triptolide in tripterygium wilfordii can inhibit T cell overactivity and block the start of autoimmune response, and the curative effect is good. Ligustrazine improves joint local microcirculation disturbance by expanding microvessels and inhibiting platelet aggregation, tanshinone has a strong anti-oxidation effect and can remove excessive oxygen free radicals generated in the inflammation process and relieve synovial cell damage, and sodium sulfate in mirabilite can promote absorption of inflammatory exudates in articular cavities and relieve swelling.

This disclosure describes a novel approach that specifically modulates the activity and / or the number of intratumoral regulatory T (Treg) cells in a subject. Such an approach can be used to reduce the number of intratumoral T regulatory cells in a subject as well as to inhibit tumor growth in a subject having a cancer without eliciting autoimmune responses.

The invention features cells, islet-like cells, pancreatic islets and organoids (e.g., human islet-like organoids or HILOs), as well as cell cultures and methods that are useful for the rapid and reliable generation of cells and organoids, such as pancreatic islets and organoids, that are sustainable in vivo and that evade immune detection, rejection and autoimmunity. The invention also features methods of treating pancreatic diseases, such as type 2 diabetes, and pancreatic cancer, using the cells, islet-like cells, pancreatic islets and organoids (e.g., HILOs) that are designed to modulate the activity of immune cells that would otherwise react against them.

The present disclosure relates to the fields of adoptive cell therapy and treatments for autoimmune diseases and disorders. The present disclosure provides engineered cells, compositions, and methods for treating patients suffering from autoimmune disorders and which are poorly treated by other methods. Specifically, the engineered cells, compositions, and methods selectivity destroy cells that mediate autoimmunity, both B and T cells, yet spare cells that modulate the autoimmune inflammatory response, e.g., regulatory T cells, or are not otherwise involved in the autoimmune response. Finally, the engineered cells are designed to avoid fratricide during their manufacturing.

The invention provides an application of celecoxib in preparation of a medicament for treating olfactory disorder, relates to the technical field of biomedicine, and is technically characterized in that the application of celecoxib in preparation of a medicament for treating olfactory disorder is provided, a non-steroidal anti-inflammatory medicament, namely celecoxib, is a selective inhibitor of epoxidase-2, and can be used for preparing a medicament for treating olfactory disorder. The traditional Chinese medicine composition is mainly used for treating osteoarthritis and rheumatoid arthritis. The COX-2 is a rate-limiting enzyme for synthesizing prostaglandin, and the expression level of the COX-2 is up-regulated when an organism is subjected to harmful stimulation (such as inflammation, oxidative stress, autoimmune response, mechanical injury and the like) and is induced by a transforming growth factor TGF-beta. In addition to regulating inflammatory response, the compound also can participate in regulating cell growth, migration, proliferation, autophagy and apoptosis. An olfactory dysfunction model induced by methimazole (MMI) is established, and the potential treatment effect of the celecoxib on the olfactory dysfunction is provided on the basis of behavioral and histological experiments, so that the celecoxib can be proved to be capable of preparing the medicine for treating the olfactory dysfunction.